This week in techniques



Licensing status

Publication and contact information

Drug platforms

Small molecule target discovery using forward genetics

In vitro, cell culture and mouse studies suggest a high throughput small
hairpin RNA screening platform could be useful for identifying the
targets of lead compounds. A cell culture screen for small molecule
inhibitors of acute lymphoblastic leukemia growth identified STF-11804,
which inhibited tumor growth at nanomolar concentrations in a range
of tumor lines. In a genomewide screen for shRNAs that enhance
STF-118804 activity, shRNA against nicotinamide phosphoribosyl transferase (NamPRT; NAMPT) increased STF-118804 sensitivity compared with shRNAs against other targets. In vitro, STF-118804 inhibited NAMPT activity. Next steps include optimization and preclinical development of STF-118804 for hematological malignancies.

SciBX 6(45); doi:10.1038/scibx.2013.1306
Published online Nov. 21, 2013

Stanford University has pending patents on STF-118804; University of California has filed patents on use of its shRNA screening platform for target identification; both sets of patents available for licensing

Mattheny, C.J. et al. Chem. Biol.; published online Oct. 31, 2013;
Contact: Michael L. Cleary, Stanford University School of Medicine, Stanford, Calif.